FindTrial
Sign In

TPC

DRUG6 trials

Sponsors

Sun Yat-sen University, Fudan University, Wenjin Yin, Memorial Sloan Kettering Cancer Center, Henan Cancer Hospital

Conditions

Advanced Breast CancerBreast CancerBreast NeoplasmHER2-negative Breast CancerHormone Receptor Positive TumorMetastatic Breast CancerMetastatic Triple Negative Breast CancerTriple-Negative Breast Cancer

Phase 2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer
RecruitingNCT05594095
Fudan UniversityAdvanced Breast Cancer, Breast Cancer, Breast Neoplasm +2
Start: 2022-12-30End: 2026-12-01Target: 620Updated: 2024-10-04
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RecruitingNCT06099769
Memorial Sloan Kettering Cancer CenterMetastatic Breast Cancer
Start: 2023-10-18End: 2027-10-01Target: 201Updated: 2026-02-25
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
RecruitingNCT07540533
Henan Cancer HospitalAdvanced Breast Cancer
Start: 2026-01-20End: 2028-08-01Target: 92Updated: 2026-04-20

Phase 3

Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
TerminatedNCT03055312
Sun Yat-sen UniversityMetastatic Triple Negative Breast Cancer
Start: 2016-12-20End: 2020-11-15Updated: 2021-01-28
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
RecruitingNCT05806060
Fudan UniversityTriple-Negative Breast Cancer
Start: 2023-04-25End: 2026-11-01Target: 134Updated: 2026-03-25

Unknown Phase

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
RecruitingNCT05876065
Wenjin YinAdvanced Breast Cancer
Start: 2023-06-01End: 2027-02-28Target: 86Updated: 2025-09-11

Related Papers

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
2025-12-04
Abstract P3-08-17: TBCRC 058: A Randomized Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, & Treatment of Physician’s Choice in Patients with Androgen Receptor-Positive Metastatic Triple-Negative or Estrogen Receptor-Low Breast Cancer (NCT06099769)
Clinical Cancer Research2025-06-13
Abstract P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial
Clinical Cancer Research2025-06-13
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
Journal of Clinical Oncology2025-05-28
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
Journal of Clinical Oncology2024-06-011 citations